15
Participants
Start Date
January 12, 2023
Primary Completion Date
June 4, 2024
Study Completion Date
June 4, 2024
Modakafusp alfa
Modakafusp alfa intravenous infusion.
Lenalidomide
Lenalidomide capsules orally.
Bortezomib
Bortezomib injection subcutaneously.
Carfilzomib
Carfilzomib intravenous infusion.
Daratumumab
Daratumumab injection subcutaneously.
Pomalidomide
Pomalidomide capsules orally.
CHU UCL Namur site Godinne, Yvoir
AZ Delta, Roeselare
New York University School of Medicine, New York
Weill Cornell Medicine/New York Presbyterian Hospital, New York
Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan Kettering Cancer Center - Main Campus, New York
NYU Langone Hospital - Long Island, Mineola
Cancer Center At Greater Baltimore Medical Center, Baltimore
Novant Health Cancer Institute - Forsyth Medical Center, Winston-Salem
Clinica Universidad de Navarra-Sede Madrid, Madrid
Novant Health Cancer Institute, Charlotte
Hospital Universitario Virgen de la Victoria, Málaga
Clinica Universidad de Navarra, Dept of Oncology, Pamplona
Rambam Health Care Campus (RHCC) - Meyer Children's Hospital - Pediatric Diabetes & Obesity Clinic, Haifa
Gabrail Cancer Center Research, Canton
Hospital Universitario La Fe de Valencia, Valencia
The University of Iowa Hospitals & Clinics, Iowa City
The University of Texas MD Anderson Cancer Center, Houston
Comprehensive Cancer Centers of Nevada, Las Vegas
Scripps Health, San Diego
University of California Davis Comprehensive Cancer Center, Sacramento
Lead Sponsor
Takeda
INDUSTRY